Mepolizumab For The Treatment Of Patients With Eosinophilic Granulomatosis With Polyangiitis: A Phase Iii Randomized, Placebo-Controlled Trial

Mepolizumab For The Treatment Of Patients With Eosinophilic Granulomatosis With Polyangiitis: A Phase Iii Randomized, Placebo-Controlled Trial

Dades bibliogràfiques
Autors principals:	Wechsler, M, Akuthota, P, Jayne, D, Khoury, P, Klion, A, Langford, C, Merkel, P, Moosig, F, Specks, U, Cid, M, Luqmani, R, Brown, J, Mallett, S, Philipson, R, Yancey, S, Steinfeld, J, Weller, P, Gleich, G
Format:	Conference item
Publicat:	American Thoracic Society 2017

Ítems similars

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
per: Wechsler, M, et al.
Publicat: (2017)

OP0130 Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: a phase iii randomised, placebo-controlled trial
per: Wechsler, M, et al.
Publicat: (2017)

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
per: Benjamin Terrier, et al.
Publicat: (2023-07-01)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
per: Ravi Ranjan Pradhan, et al.
Publicat: (2019-01-01)

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis
per: Giuseppe A. Ramirez, et al.
Publicat: (2022-12-01)

Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis
per: Falk, R, et al.
Publicat: (2011)

Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.
per: Falk, R, et al.
Publicat: (2011)

Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.
per: Falk, R, et al.
Publicat: (2011)

Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis.
per: Falk, R, et al.
Publicat: (2011)

Mepolizumab as an effective treatment in a case of hypophysitis in eosinophilic granulomatosis with polyangiitis
per: Jessy Chen, et al.
Publicat: (2023-06-01)

Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis
per: Moriyasu Anai, et al.
Publicat: (2022-04-01)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
per: Masanobu Ueno, et al.
Publicat: (2021-03-01)

Earlier continuous administration of mepolizumab for eosinophilic granulomatosis with polyangiitis based on cutaneous findings
per: Takaharu Ikeda, et al.
Publicat: (2023-08-01)

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
per: Charlene Desaintjean, et al.
Publicat: (2024-03-01)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
per: Andrea Portacci, et al.
Publicat: (2023-10-01)

Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
per: Nami Masumoto, et al.
Publicat: (2023-05-01)

Effective treatment with mepolizumab in a patient with severe eosinophilic granulomatosis with polyangiitis complicated with small intestine perforation
per: Mari Sato, et al.
Publicat: (2023-01-01)

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study
per: Masanobu Ueno, et al.
Publicat: (2022-06-01)

Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
per: Christian Dejaco, et al.
Publicat: (2015-01-01)

A Case of Effective Mepolizumab Induction Therapy for Severe Eosinophilic Granulomatosis with Polyangiitis Diagnosed by Eosinophilic Cholecystitis and Interstitial Nephritis
per: Keita Hattori, et al.
Publicat: (2021-01-01)

Efficacy and safety of belimumab in combination with azathioprine for remission maintenance in granulomatosis with polyangiitis and microscopic polyangiitis: a multicenter randomized, placebo-controlled study
per: Jayne, D, et al.
Publicat: (2017)

Reduction in ANCA levels associated with mepolizumab add-on treatment in eosinophilic granulomatosis with polyangiitis: Case series and literature review
per: Yosuke Kamide, et al.
Publicat: (2024-01-01)

Eosinophilic granulomatosis with polyangiitis: sequential use of mepolizumab following rituximab for inadequate asthma control despite vasculitis remission
per: B. Cremonezi Lammoglia, et al.
Publicat: (2023-12-01)

Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics
per: David R.W. Jayne, et al.
Publicat: (2024-01-01)

Eosinophilic granulomatosis with polyangiitis: an overview
per: Andrea eGioffredi, et al.
Publicat: (2014-11-01)

Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis
per: David Jayne, et al.
Publicat: (2019-06-01)

A MODEL TO PREDICT CARDIOVASCULAR EVENTS IN PATIENTS WITH NEWLY DIAGNOSED WEGENER'S GRANULOMATOSIS AND MICROSCOPIC POLYANGIITIS
per: Suppiah, R, et al.
Publicat: (2011)

Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7.
per: Merkel, P, et al.
Publicat: (2005)

Improvement of Chronic Rhinosinusitis and Reduction of the Myeloperoxidase-Antineutrophil Cytoplasmic Antibody Titer in a Patient with Eosinophilic Granulomatosis with Polyangiitis by Additional Mepolizumab
per: Shin-ya Tamechika, et al.
Publicat: (2021-01-01)

Clinical Manifestations and Long‐Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America
per: Irena Doubelt, et al.
Publicat: (2021-06-01)

Granulomatosis with polyangiitis
per: Yu Zhu, et al.
Publicat: (2024-01-01)

Granulomatosis with polyangiitis
per: Zubayer Ahmad, et al.
Publicat: (2016-12-01)

Nasal Cytology in Eosinophilic Granulomatosis with Polyangiitis
per: David Longhino, et al.
Publicat: (2024-06-01)

Burden of eosinophilic granulomatosis with polyangiitis in Europe
per: Rupert W. Jakes, et al.
Publicat: (2024-08-01)

Renal involvement in eosinophilic granulomatosis with polyangiitis
per: Francesco Reggiani, et al.
Publicat: (2023-09-01)

Endobronchial Lesion in Eosinophilic Granulomatosis with Polyangiitis
per: Guan-Liang Chen, et al.
Publicat: (2017-12-01)

Eosinophilic Cholecystitis Associated with Eosinophilic Granulomatosis with Polyangiitis
per: Hiroyuki Ito, et al.
Publicat: (2020-12-01)

Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study
per: Mayu Shiomi, et al.
Publicat: (2024-10-01)

Psoriasis‐like skin rash triggered by a local infection in a patient with eosinophilic granulomatosis with polyangiitis that was well controlled by mepolizumab treatment
per: Naho Yokota, et al.
Publicat: (2023-06-01)

Refractory diffuse alveolar hemorrhage caused by eosinophilic granulomatosis with polyangiitis in the absence of elevated biomarkers treated successfully by rituximab and mepolizumab: A case report
per: Akihiro Shiroshita, et al.
Publicat: (2019-01-01)